36341-25-0

基本信息
2-(4-羟基-3-甲氧基苯基)苯并噻唑
4-(苯并[D]噻唑-2-基)-2-甲氧基苯酚
Y-109
YL-109
Y-109
Y109
Phenol, 4-(2-benzothiazolyl)-2-methoxy-
4-(benzo[d]thiazol-2-yl)-2-Methoxyphenol
4-(1,3-Benzothiazol-2-yl)-2-methoxyphenol
2-(4-HYDROXY-3-METHOXYPHENYL)BENZOTHIAZOLE
4-(3H-1,3-benzothiazol-2-ylidene)-2-methoxycyclohexa-2,5-dien-1-one
物理化学性质
制备方法

121-33-5

137-07-5
![4-(苯并[D]噻唑-2-基)-2-甲氧基苯酚](/CAS/GIF/36341-25-0.gif)
36341-25-0
以香兰素和2-氨基苯硫酚为原料合成2-(4-羟基-3-甲氧基苯基)苯并噻唑的一般步骤:在催化反应中,将香兰素(3mmol)、2-氨基苯硫酚(3mmol)和CdS纳米球(5mg)的混合物置于100mL双壁石英烧瓶中,该烧瓶配备有水入口和出口以维持反应温度在室温。反应在甲醇(20mL)中进行,并在搅拌条件下将反应混合物暴露于可见光下照射指定时间(参见表3)。反应进程通过薄层色谱(TLC)和气相色谱(GC)监测。反应完成后,通过旋转蒸发去除甲醇,将残余物溶解于二氯甲烷中。通过离心分离催化剂与反应混合物。随后,蒸发二氯甲烷至干,产物通过硅胶G60柱色谱法进行纯化。
参考文献:
[1] Chemistry Letters, 2004, vol. 33, # 3, p. 274 - 275
[2] Tetrahedron Letters, 2013, vol. 54, # 9, p. 1090 - 1096
[3] Heterocycles, 2007, vol. 71, # 8, p. 1837 - 1842
[4] Research on Chemical Intermediates, 2015, vol. 41, # 10, p. 7509 - 7516
[5] Journal of Heterocyclic Chemistry, 2009, vol. 46, # 1, p. 91 - 95
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2025/05/22 | HY-18619 | 4-(苯并[D]噻唑-2-基)-2-甲氧基苯酚 YL-109 | 36341-25-0 | 5mg | 550元 |
2025/05/22 | HY-18619 | 4-(苯并[D]噻唑-2-基)-2-甲氧基苯酚 YL-109 | 36341-25-0 | 10mM * 1mLin DMSO | 600元 |
2025/05/22 | HY-18619 | 4-(苯并[D]噻唑-2-基)-2-甲氧基苯酚 YL-109 | 36341-25-0 | 10mg | 900元 |
常见问题列表
YL-109 (0.001-10 μM; 96 h or 24 h) inhibits cell proliferation, motility, and invasiveness in breast cancer cells.
YL-109 (1 μM) increases both CHIP mRNA and protein levels in MDA-MB-231 cells.
Cell Proliferation Assay
Cell Line: | MCF-7 and MDA-MB-231 cells |
Concentration: | 0.001, 0.01, 0.1, 1, 10 μM |
Incubation Time: | 96 hours |
Result: | Strongly inhibited cell proliferation of MCF-7 and MDA-MB-231 cells in a dose-dependent manner (IC 50 =85.8 nM and 4.02 μM, respectively). |
YL-109 (15 mg/kg; s.c. for every 2 d) inhibits both tumor growth and cancer metastasis of breast cancer cells in vivo.
Animal Model: | BALB/cAjcl-nu/nu female mice (4-5 weeks) inoculated with MCF-7 or MDA-MB-231 cells |
Dosage: | 15 mg/kg |
Administration: | S.c. every 2 days for 63 days |
Result: | Suppressed tumor growth in mice injected with MCF-7 and MDA-MB-231 cells. |